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Abstract
This review is intended to provide histopathologists with guidelines for clinical assessment, specimen handling
and diagnostic reporting of benign and malignant primary bone tumours. Information from radiology, surgical,
oncology and other clinical colleagues involved in the diagnosis and treatment of primary bone tumours should
be properly assessed before undertaking a structured approach to specimen handling and histological reporting.
This ensures that the information needed for planning appropriate treatment of these complex tumours is
provided. Consistency in diagnostic evaluation with respect to both terminology and report content facilitates
liaison at multidisciplinary bone tumour meetings and collaboration between cancer units and networks, as well
as providing a common database for audit of the clinical, radiological and pathological aspects of bone
tumours.
1. Introduction
This review is intended to provide histopathologists with
guidelines for specimen handling and diagnostic report-
ing of benign and malignant primary bone tumours; the
principles of specimen handling required for assessment
of secondary bone tumours are similar. As many pri-
mary bone tumours are uncommon or rare, experience
in diagnostic orthopaedic pathology is required to main-
tain a high standard of histological reporting of bone
tumours; participation in an external quality assessment
(EQA) scheme which includes bone tumour pathology is
recommended.
Close cooperation is needed between the histopatholo-
gist and radiology, surgical, oncology and other clinical
colleagues in the diagnosis and treatment of bone
tumours; consensus clinical practice guidelines for
managing bone sarcomas have been recently published
[1,2]. All primary malignant bone tumour cases should
be discussed at a properly constituted sarcoma multidis-
ciplinary team (MDT) meeting.
2. Classification, grading & staging of primary
bone tumours
Primary benign and malignant bone tumours vary
widely in their clinical behaviour and pathological fea-
tures. The nomenclature and classification of primary
bone tumours is based mainly on the pathway of
tumour cell differentiation; this is usually evidenced by
t h et y p eo fc o n n e c t i v et i s s u em a t r i xf o r m e db yt u m o u r
cells. The histogenesis of many primary bone tumours,
however, is not known and a number of bone tumours
are by convention classified by distinct morphological or
clinicopathological features (eg giant cell tumour of
bone) or by karyotypic and molecular genetic abnormal-
ities (eg Ewing’s sarcoma) [3,4]. The 2002 World Health
Organisation (WHO) classification of bone tumours is
recommended for histological reporting of bone
tumours as it is well-recognised and widely employed
internationally [3]. [Table 1].
Histological grading of a bone sarcoma provides a
guide as to its biological behaviour and is based largely
on the degree of cellular and nuclear pleomorphism, cel-
lularity, mitotic activity and the extent of tumour necro-
sis [3-7]. Some high-grade monomorphic tumours,
(such as Ewing’s sarcoma), and some other specific
tumour types cannot be graded accurately in this way
and the tumour grade is defined by the specific
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grading recommendations of the College of American
Pathologists is shown in Table 2 (7). In this scheme,
conventional chondrosarcoma is divided into Grade 1
(low), Grade II (intermediate) and Grade III (high) on
the basis of cellularity and nuclear pleomorphism, as
these features have been shown to correlate with
prognosis [7,8]; some specific chondrosarcoma subtypes
are considered high-grade (eg mesenchymal chondrosar-
coma), or low-grade (clear cell chondrosarcoma) Con-
ventional osteosarcoma and most osteosarcoma
subtypes are considered high-grade with the exception
of low-grade central osteosarcoma and periosteal osteo-
sarcoma (both low-grade) and periosteal osteosarcoma
Table 1 WHO classification and SNOMED codes of primary bone tumours [3]
Cartilage tumours Giant cell tumours
Osteochondroma 9210/0* Giant cell tumour 9250/1
Chondroma 9220/0 Malignancy in giant cell tumour 9250/3
Enchondroma 9220/0
Periosteal chondroma 9221/0
Multiple chondromatosis 9220/1 Notochordal tumours
Chondroblastoma 9230/0 Chordoma 9370/3
Chondromyxoid fibroma 9241/0
Chondrosarcoma 9220/3
Central, 1° and 2° 9220/3 Vascular tumours
Peripheral 9221/3 Haemangioma 9120/0
Dedifferentiated 9243/3 Angiosarcoma
Mesenchymal 9240/3
Clear cell 9242/3
Smooth muscle tumours
Leiomyoma 8890/0
Osteogenic tumours
Osteoid osteoma 9191/0
Osteoblastoma 9200/0
Osteosarcoma 9180/3 Lipogenic tumours
Conventional 9180/3 Lipoma 8850/0
Chondroblastic 9181/3 Liposarcoma 8850/3
Fibroblastic 9182/3
Osteoblastic 9180/3
Telangiectatic 9183/3 Neural tumours
Small cell 9185/3 Neurilemmoma 9560/0
Low grade central 9187/3
Secondary 9180/3
Parosteal 9192/3 Miscellaneous tumours
Periosteal 9193/3 Adamantinoma 9261/3
High grade surface 9194/3 Metastatic malignancy
Fibrogenic tumours Miscellaneous lesions
Desmoplastic fibroma 88230 Aneurysmal bone cyst 33640
Fibrosarcoma 88103 Simple cyst 33400
Fibrous dysplasia 74910
Osteofibrous dysplasia 92620
Fibrohistiocytic tumours Langerhans cell histiocytosis 97511
Benign fibrous histiocytoma 8830/0 Erdheim-Chester disease 77920
Malignant fibrous histiocytoma 8830/3 Chest wall hamartoma 75580
Ewing sarcoma
Ewing sarcoma 9260/3
Haematopoietic tumours
Plasma cell myeloma 9732/3
Malignant lymphoma, NOS 9590/3
Mangham and Athanasou Clinical Sarcoma Research 2011, 1:6
http://www.clinicalsarcomaresearch.com/content/1/1/6
Page 2 of 13(intermediate-grade)[7,9]. Most chordomas generally
behave as intermediate-grade locally aggressive tumours
which frequently recur and can metastasise. Osteofi-
brous dysplasia-like (differentiated) adamantinoma rarely
metastasises and is considered low-grade whereas classic
adamantinoma has significant metastatic potential and is
considered intermediate-grade. Grading is not useful in
predicting the behaviour of conventional giant cell
tumour of bone, but malignant giant cell tumour is con-
sidered high-grade. Other sarcoma types that develop in
both soft tissue and bone are graded according to the
French Federation of Cancer Centres Sarcoma Group
(FNCLCC) grading system [10].
Bone sarcomas are staged using either the American
Joint Committee on Cancer (AJCC) TNM staging sys-
tem or the Musculoskeletal Tumour Society (MSTS)
Staging System (SSS) [11-14]. (Tables 3, 4). The AJCC
and MSTS systems have many features in common. The
most recent version of the AJCC staging of primary
bone malignancies has subdivided Stage 1 and Stage II
tumours on the basis of tumour size rather than
intraosseous or extraosseous extent of the tumour (as in
the MSTS system). Specifically, tumour size of less than
8 cm maximum dimension is considered a favourable
prognostic indicator. The current AJCC system also
recommends that tumours with skip metastases are clas-
sified separately as Stage III, and that Stage IV tumours
associated with distant metastases are subdivided on the
b a s i so fw h e t h e rt h e s ea r eo n l yt ot h el u n g( S t a g eI V A )
or to other sites, including bone (Stage IVB). MSTS sta-
ging uses a two-grade system of histological grading
whereas AJCC staging uses a 4-grade system, with grade
1 and 2 effectively considered low-grade and grades 3
and 4, high grade [14]. Formal staging of a bone tumour
should be carried out at a sarcoma MDT meeting where
clinical, radiological and histological information can be
obtained.
3. Clinical & radiological information required for
the pathological diagnosis of bone tumours
Histopathological assessment of a bone tumour needs to
take into account the clinical background and features
of the lesion, its radiological appearances and the results
of relevant laboratory investigations [15,16] (Tables 5,
6). Diagnostic evaluation and treatment should optimally
be carried out at a centre which specialises in the diag-
nosis and treatment of bone tumours.
Relevant clinical information should be provided on
the pathology request form and its content should be
recorded in the final pathology report. The age of the
patient is crucial for bone tumour diagnosis as a num-
ber of bone tumours, both benign and malignant, tend
to develop most commonly within a given age range.
Some tumours and tumour-like lesions have a predilec-
tion to arise in certain bones (eg simple bone cyst
occurs most often in the proximal humerus of a child
or adolescent). Most bone tumours present with bone
pain and swelling. Bone pain is dull, aching and charac-
teristically worse at night. Rapid growth is characteristic
of some malignant tumours but is also seen in some
benign tumours and tumour-like lesions, such as aneur-
ysmal bone cyst, eosinophilic granuloma and osteomye-
litis. A history of trauma may be notable in cases where
a post-traumatic lesion (eg haematoma) is a possible
diagnosis. Local and systemic signs of infection need to
be distinguished from those associated with the growth
of a bone tumour, such as Ewing’s sarcoma. Information
regarding a pre-existing skeletal condition should be
provided, including developmental conditions where
there are multiple skeletal lesions (eg fibrous dysplasia,
osteochondromatosis). It is also important to receive
information on any relevant extraskeletal disease (eg his-
tory of carcinoma) elsewhere in the body. Racial occupa-
tional and treatment factors may also be relevant in the
assessment of a bone tumour [16,17].
The results of laboratory investigations which may
help in evaluating a bone lesion should be communi-
cated to the reporting pathologist [18]. Details of the
white blood cell count and erythrocyte sedimentation
rate should be noted if there is a possibility that the
lesion is a bone infection, eosinophilic granuloma, leu-
kaemia or other haematological malignancy. Ewing’s sar-
coma and ‘toxic’ osteoclasts may present with clinical
and laboratory features that resemble osteomyelitis. If
myeloma is suspected, protein electrophoresis for the
Table 2 Bone sarcoma grading
Grade
1
Low-grade central osteosarcoma
Parosteal osteosarcoma
Low-grade chondrosarcoma
Clear cell chondrosarcoma
Osteofibrous dysplasia-like adamantinoma
Grade
2
Periosteal osteosarcoma
Intermediate - grade chondrosarcoma
Classic adamantinoma
Chordoma
Grade
3
Osteosarcoma (conventional, telangieclatic, small cell,
secondary,
high-grade surface)
Ewing’s sarcoma
High-grade chondrosarcoma
Dedifferentiated chondrosarcoma
Mesenchymal chondrosarcoma
Dedifferentiated chordoma
Malignant giant cell tumour
(Modified from reference [7])
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nents in the serum or urine should be undertaken.
Laboratory tests reflecting bone turnover, such as the
serum calcium, phosphate and alkaline phosphatase
should also be known, particularly if there is a need to
exclude a metabolic cause for the development of a
bone tumour, such as a “brown tumour” of hyperpar-
athyroidism or Paget’s disease. The alkaline phosphatase
m a ya l s ob ee l e v a t e di no s t e o s a r c o m a ,‘blastic’ metas-
tases, fracture, polyostotic fibrous dysplasia and other
conditions. The acid phosphatase may be elevated in
prostate carcinoma.
Radiological information is essential for bone tumour
diagnosis [15,19] and it is strongly recommended that,
wherever possible, the pathologist should personally
view the radiological images of a bone tumour before
Table 3 TNM staging system for bone tumours
T - Primary tumour
TX Primary tumour cannot be assessed
T0 No evidence of primary tumour
T1 Tumour 8 cm or less in greatest dimension
T2 Tumour more than 8 cm in greatest dimension
T3 Discontinuous tumours in the primary bone site
N - Regional lymph nodes
NX Regional lymph nodes cannot be assessed
N0 No regional lymph node metastasis
N1 Regional lymph node metastasis
M - Distant metastasis
MX Distant metastasis cannot be assessed
M0 No distant metastasis
M1 Distant metastasis
M1a Lung
M1b Other distant sites
G - Histologic grade
GX Grade cannot be assessed
G1 Well differentiated - low grade
G2 Moderately differentiated - low grade
G3 Poorly differentiated - high grade
G4 Undifferentiated - high grade*
Stage grouping
Stage Tumour (T) Node (N) Metastasis (M) Grade (G)
Stage IA T1 NO MO G1, 2 low grade
Stage IB T2 NO MO G1, 2 low grade
Stage IIA T1 NO MO G3, 4 high grade
Stage IIB T2 N0 MO G3, 4 high grade
Stage III T3 NO MO Any G
Stage IVA Any T NO M1a Any G
Stage IVB Any T N1 Any M Any G
Any T Any N M1b Any G
*Ewing’s sarcoma is classified as high grade.
Table 4 Musculoskeletal Tumour Society staging system
for bone tumours
Benign tumours (G0)
Stage I - Inactive, latent (G0)
Stage II - Active (G0)
Stage III - Aggressive (G0)
Malignant tumours
Stage I - Low grade (G1)
Stage II - High grade (G2)
Stage III - Low or high grade tumours with metastases
Subdivisions
A - Intracompartmental
B - Extracompartmental
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should be recorded in the pathology report.
The precise anatomical location of a lesion in bone is
important because tumours have a tendency not only to
develop more commonly in certain bones but also more
frequently to involve the particular anatomical region of
an affected bone. It should also be evident from the
radiology whether a lesion has originated in bone or
extended into it from surrounding soft tissues.
The matrix composition of the lesion may point to
specific diagnostic possibilities (eg calcification within
cartilage tumour or ossification within a bone-forming
tumour). The interface between the lesion and sur-
rounding bone, particularly whether the lesion is well or
poorly defined, should be noted as this may favour a
particular benign or malignant diagnosis. A sclerotic rim
is commonly present around slow growing lesions and
usually points to a benign diagnosis. A non-sclerotic
margin is usually found around a more rapidly growing
bone lesion; malignant lesions are commonly poorly
defined and have a broad zone of transition.
The pattern of bone destruction should be identified
as it indicates the rate of growth of a bone lesion. A
geographic pattern of bone destruction is characterised
by the presence of well-circumscribed lytic areas (maxi-
mum dimension more than 1 cm) with a well-defined
margin; this reflects the slow growth rate of these
lesions, which are usually benign tumours (eg non-ossi-
fying fibroma) or locally aggressive/low-grade malignant
tumours (eg giant cell tumour of bone, low-grade
chondrosarcoma). A rim of sclerosis between normal
host bone and the lytic area may or may not be present.
A moth-eaten pattern of bone destruction is charac-
terised by the presence of multiple small lytic areas
(usually 2-5 mm) separated by identifiable bone; this
indicates an aggressive pattern of growth and is most
often seen in malignant neoplasms, although it can be
seen in some forms of osteomyelitis and eosinophilic
granuloma. A permeative pattern of bone destruction is
characterised by diffuse marrow involvement in which
there are multiple tiny lytic areas (< 1 mm maximum
dimension). This is usually accompanied by a broad
zone of transition and reflects rapid growth of a bone
lesion. A permeative pattern occurs in malignant
t u m o u r ss u c ha sE w i n g ’s sarcoma and osteosarcoma,
but can also be seen in some benign entities such as
osteomyelitis and eosinophilic granuloma.
Radiological evidence of extension of the tumour
through the bone cortex and involvement of surround-
ing soft tissue should be noted as this provides evidence
of a locally aggressive or malignant tumour. The nature
of the periosteal reaction associated with a bone lesion
oftens reflects the growth rate of the tumour. When the
tumour grows slowly, the periosteum forms a thick layer
of bone. Multiple layers of periosteal new bone are
formed when there is a succession of fast and slow
growth phases associated with the enlargement of the
underlying lesion. The presence of tumour on both
sides of the cortex (which is not yet destroyed) often
indicates a very aggressive lesion.
Table 5 BONE TUMOUR DIAGNOSIS: CLINICAL FEATURES
￿ Age (date of birth) and sex of the patient.
￿ Racial background [17]
￿ A record of the anatomical bone involved by tumour.
￿ Clinical features associated with the tumour, such as nature and duration of signs and symptoms, including the presence or absence of pain,
swelling, deformity, and relation to a previous traumatic episode.
￿ The presence or absence of a pre-existing or concomitant skeletal disease, history of familial syndrome or other relevant disease predisposing to
tumour development.
￿ Occupational or treatment (eg chemotherapy, radiation therapy) history that may predispose to bone malignancy.
￿ The presence or absence of systemic features of disease.
￿ Results of relevant laboratory investigations (see text).
Table 6 BONE TUMOUR DIAGNOSIS: RADIOLOGICAL FEATURES
￿ The precise anatomical location of the lesion in the affected bone (ie epiphyseal, metaphyseal, diaphyseal, medullary, cortical, periosteal or
extraosseous in location).
￿ The size of the lesion
￿ The matrix composition of the lesion
￿ The nature of the zone of transition or interface between the lesion and surrounding bone.
￿ The pattern of bone destruction
￿ The presence or absence of infiltration of medullary bone.
￿ The presence or absence of cortical destruction and soft tissue involvement
￿ The nature of the periosteal reaction
￿ The presence of multiple lesions within bone
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be determined as this may suggest particular conditions
such as multiple cartilage tumours (eg enchondromato-
sis, multiple osteochondromas) or Langerhans cell histo-
cytosis (LCH). This feature is also useful in assessing
whether a malignant tumour is more likely to be pri-
mary or secondary. With regard to primary malignant
bone tumours, it may also point to a diagnosis of multi-
focal osteosarcoma or metastatic Ewing’s sarcoma.
4. General handling of bone tumour specimens
before dissection
The following information should be recorded for all
bone tumour specimens:-
1. Patient and specimen identification details including
patient name, age (date of birth), sex, hospital and surgi-
cal pathology identification numbers.
2. Identification of the type of specimen received eg
fine or core needle (closed) biopsy, surgical (open)
biopsy, curettage, excision (segmental resection/en bloc),
limb salvage, amputation or specific type of complex
resection (eg hemipelvectomy).
It is often useful to receive specimens fresh (unfixed)
in the laboratory. This permits the use of a number of
specialised investigations where appropriate. These
include the provision of material for frozen section diag-
nosis, the use of specific fixatives for histochemistry and
snap freezing of tissue for molecular genetic studies
[1,7,20,21]. Fresh tissue can also be sent for microbiolo-
gical culture or cytogenetic studies. Where the above
studies are not anticipated or where there is likely to be
a delay in the processing the specimen should be imme-
diately fixed in 10% neutral buffered formalin. It is
important that specimens are not placed in a freezer as
this may result in formation of ice crystal artefacts.
It may be useful to specify whether the specimen was
received fresh or in fixative and to record details of spe-
cimen transport to the laboratory; it should be noted if
this has led to a delay or problems in processing. 10%
neutral buffered formalin fixation is routinely used in
most laboratories and is generally suitable for bone spe-
cimens. Fixation in absolute alcohol is useful for identi-
fying glycogen in Ewing sarcoma cells. Small biopsy
fragments containing only cancellous bone fragments or
tumour tissue containing small amounts of bone can be
d e c a l c i f i e da n df i x e di no n eo v e r n i g h ts t e pt h r o u g ht h e
use of 5% trichloracetic acid or ethylene diaminetetrace-
tic acid (EDTA) dissolved in 10% buffered formalin.
Decalcification with strong (eg nitric) or weak (eg for-
mic) acid solutions is required for the histological pro-
cessing of most bone tumour specimens. To shorten the
period required for decalcification, samples of a tumour
biopsy that are not heavily mineralised should be
selected; 2-4 mm thick slices should be submitted for
decalcification from large specimens. Where there is a
need for rapid diagnosis, 5% nitric or 20% formic acid
can be used for rapid decalcification. Immersion of bone
biopsy specimens in strong acids should not exceed 24
hours. The mineralisation status of the specimens
should be constantly monitored. This is usually carried
out by specimen radiography but chemical (eg calcium
oxalate) tests are also available to determine the end
point of decalcification. EDTA made neutral with
sodium hydroxide solution removes calcium more
slowly but provides better preservation of tissue and
cytological details as well as antigenicity. It should be
noted that most ancillary stains can be employed with-
out modification to tissues that are decalcified even in
strong acids; the antigenicity of many common epitopes
is not abrogated by decalcification in strong acids [22].
However, strong acids can interfere with molecular
genetic analysis [23].
In general, decalcified tissue is processed in the same
way as undecalcified tissue. After paraffin embedding,
blocks should be trimmed, placed in the freezer for 30
minutes and then on an ice tray before 3-5 μm sections
are cut. A standard rotary microtome is suitable for rou-
tine use; larger sections can be cut on a sledge micro-
tome. Haematoxylin-eosin stains are used routinely for
morphological diagnosis. Ehrlich’so rC o l e ’sf o r m u l af o r
haematoxylin is recommended as it gives the best differ-
ential staining of calcified bone, osteoid and cement
lines. Other useful ancillary stains include PAS (+/- dia-
stase), reticulin, toluidine blue, Alcian blue, Perls, Congo
Red and Masson-Fontana.
5. Frozen section and aspiration cytology of bone
tumours
Frozen section examination of bone tumours should
only be carried out by pathologists who have some
experience of osteoarticular pathology and who have
knowledge of the clinical background and radiological
appearances of the lesion; the usefulness of frozen sec-
tion histological examination is predicated on close
cooperation between the surgeon, radiologist and
pathologist [1,2,20,21]. Frozen section histology provides
information on:-
￿ Adequacy of the biopsy specimen.
￿ The nature of the lesion.
￿ Ancillary investigations which may be required for
diagnosis.
￿ Adequacy of resection margins.
Frozen section analysis is particularly useful in deter-
mining whether the sampled tissue is adequate and
representative of the biopsied lesion. It is also used
intraoperatively for the examination of resection mar-
gins to determine the level of excision or amputation of
a bone tumour. Frozen section also has a diagnostic
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nature of the lesion. It is particularly useful in this
regard in indicating whether a lesion is likely to be
inflammatory or neoplastic; this may be helpful in
directing the surgeon to take further samples for micro-
biological culture or carrying out cytogenetic and mole-
cular genetic analysis. In some cases, the appearances of
the lesion are sufficiently characteristic to permit a defi-
nitive diagnosis; in the appropriate clinical and radiolo-
gical context, this may permit immediate surgical
treatment of the lesion. A definitive diagnosis of bone
tumour, however, should not be based on the examina-
tion of frozen sections alone. Gross specimens sub-
mitted for frozen section should be carefully evaluated
for the presence of heavily mineralised tissues, such as
fragments of cortical bone, which should be removed
from the samples submitted for frozen section. Stained
touch or imprint preparations can be used to provide
supplementary information to a frozen section diagnosis
and are particularly useful if the tissue is heavily minera-
lised. Imprint preparations are particularly useful in the
diagnosis of round cell tumours of bone, such Ewing’s
sarcoma, lymphoma, and osteosarcoma, but may also
occasionally suggest a diagnosis of osteomyelitis, eosino-
philic granuloma or carcinoma.
Aspiration cytology can also provide useful informa-
tion on bone tumours [24-27]. However, it has a rela-
tively limited role in the diagnosis of these neoplasms.
As with imprint preparations, when combined with fro-
zen section histology, it can provide important cytologi-
cal information that may point to a specific diagnosis. It
may have a particular role in the diagnosis of possible
sarcoma recurrence or metastasis of previously well-
documented neoplasms. Under these circumstances,
when combined with adequate radiological and clinical
information, a diagnosis can often be suggested.
6. Bone tumour biopsy and curettage specimen
handling
Biopsy specimens for histological examination are
usually obtained by either open (surgical) biopsy, or
closed (percutaneous) needle biopsy [28-30].
Closed needle biopsy is an effective and safe technique
and is often used in the initial diagnosis of a bone
tumour. Most lesions can be biopsied in this way, yield-
ing adequate material to permit an experienced patholo-
gist to make a diagnosis. With this technique there is
little risk of dissemination of the tumour in the course
of the procedure. The principal disadvantage of needle
biopsy is that it provides less material for histological
examination than an open biopsy; this may limit the
amount of diagnostic information that can be obtained
from the biopsy. In addition, as much of the biopsy tis-
sue is required for histological diagnosis, this can limit
or preclude the use of other investigations ( eg molecu-
lar genetics), which may provide supplementary diagnos-
tic information. An open biopsy specimen generally
provides more material for histological examination
than a closed biopsy. Open biopsy is commonly
employed for the diagnosis of bone tumours in children
from whom it may be difficult to obtain a closed biopsy
specimen. It is recommended that an open biopsy is car-
ried out at the centre where the tumour is to be treated
as this ensures that the biopsy tract is removed at the
time of definitive surgery. When combined with frozen
section examination of the biopsy sample, this technique
ensures that the biopsy tissue is adequate and represen-
tative of the lesion.
Most biopsy specimens require at least three hours
fixation. Core needle biopsy specimens, if properly fixed,
maybe decalcified overnight in acid or a chelating agent.
If the core is 5 mm or more in thickness, it should be
divided. In general, if ancillary studies are anticipated
t h e nam i n i m u mo ft h r e ec o r e sm a yb en e e d e d .Ag e n -
eral gross description of the biopsy specimen should be
given including dimensions, consistency, colour [5,7,19].
The presence of necrosis, thrombus, fibrin clot, myxoid
change, bone cartilage and fibrous tissue should be
noted. It may be possible to separate soft areas of the
tumour from calcified areas of the tumour; the former
may be submitted for frozen section or rapid histological
diagnosis Handling of curettage specimens is essentially
similar to that for core needle biopsies in terms of gross
description and specimen handling. If a large amount of
curetted material is received, then this should be
sampled extensively (about 1 section per cm. Specimens
should be submitted for overnight formalin fixation and
decalcification.
The surgical pathology report on a biopsy or curettage
specimen should record the morphological and cytologi-
cal features of the tumour, including degree of pleo-
morphism, mitotic count and the presence of tumour
necrosis. The report should contain the histological
diagnosis (or differential diagnosis), indicating where
possible details of the specific tumour type (+/- subtype)
and tumour grade. Even when a specific diagnosis
appears to have been established by means of a biopsy,
careful histological study of the resection and amputa-
tion specimen needs to be carried out as the same histo-
logical features may not be present throughout a
tumour and the appearances of the tumour tissue can
change over time or as a result of treatment.
7. Specimen handling and macroscopic
description of an amputation or segmental
resection for bone tumour
Orthopaedic amputation and segmental resection speci-
mens are often large and will not fix adequately if left
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promptly after arrival in order to expose the key tissues
and tumour for subsequent fixation [5-7,19]. The
volume ratio of fixative to specimen large specimens
should be at least 3:1.
Before dissecting an amputation or large segmental
resection for bone tumour, the pathologist should
review the pre-surgical clinical history, relevant radiol-
ogy and biopsy pathology report(s).
The type of amputation (e.g. left hindquarter amputa-
tion, right forequarter amputation, right below nee
amputation), or resection (eg left distal femoral resec-
tion left second toe amputation) should be noted and a
digital photograph of the intact specimen taken from at
least two aspects. The following are guidelines for large
specimen dissection:
1. Measure and record the length of the amputation
or resection specimen in three dimensions. For amputa-
tions, the length between the major joints and the dis-
tance between the tumour and the osteotomy site and
the closest soft tissue amputation site should be noted;
for resections, the distance between the palpable tumour
and the osteotomy site should be recorded. It may be
useful to include a measure of the circumference at the
level of the tumour. Specimen radiographs may aid in
determining the extent of bone, joint and soft tissue
involvement at this stage.
2. Record the size and position of any previous surgi-
cal scars. Determine the presence, position, and dimen-
sions of previous biopsy sites in an amputation
specimen. For resection specimens, record the size and
position of the excised skin ellipse (which should be
included in the biopsy tract).
3. Search for the major lymph node groups and iden-
tify and place them in separate containers of fixative.
4. Cut a cross section of the proximal bone margin
with a bandsaw.
5. Take samples of the major vessels at the amputa-
tion site and place in a separate container of fixative.
6. Dissect all the soft tissues (down to the periosteum)
around the involved bone. If there is any indication
(from the radiographs or at the time of dissection) of
soft tissue tumour extension, dissect around this area
and keep it in continuity with the bone. Unless the
tumour involves an adjacent joint, the entire bone con-
taining the tumour should be excised. If, from the radio-
graphs, the tumour involves an adjacent joint, cut
through the adjacent, non-involved bone transversely
with the band saw approximately 5-10 cms from the
joint, and then excise the involved bone, joint and
attached uninvolved length of bone.
7. Once the key part of the amputation specimen has
been dissected out, a plain radiograph of the intact
tumour and bone can be taken using a laboratory X-ray
machine. This will aid the subsequent decision on the
preferred initial slice through the specimen.
8. Take tissue samples for histology of any previous
surgical sites or biopsy tracts in order to determine the
presence/absence of tumour implantation.
9. Long bones containing the tumour (and the excised
adjacent joint, if applicable), should be cut longitudinally
with a band saw. In most cases, the cut should be in the
coronal plane, dividing the specimen into anterior and
posterior halves. When the tumour is a surface tumour
involving the anterior or posterior aspect of the bone
(eg parosteal osteosarcoma, surface chondrosarcoma), a
sagittal section may be preferable for tumours of unu-
sual shape/site of origin. It is nearly always sufficient to
take an initial coronal slice and then subsequent addi-
tional slices to complement the coronal slice. For hind-
quarter and forequarter amputations, and for pelvic and
scapular bone tumours, it may be necessary to cut the
bone obliquely; in these bones the ideal cut usually
involves the joint (hip and shoulder, respectively) and
includes the area of tumour origin/main areas of tumour
with subsequent slices used to sample any extra-osseous
tumour extension.
10. After fixing the sliced bone specimen for a further
24 hours, a cut is made using a band saw parallel to the
initial cut in order to provide a slice of the bone
tumour. The thickness of this slice should be approxi-
mately 5 mm. This slab should be radiographed to pro-
vide a specimen radiograph. For bone resection
specimens, the surgical tissue margins should be taken
after fixation. Medial, lateral, anterior and posterior (as
well as the osteotomy transverse slice) margins should
be taken as minimum. Further margins can be taken if
there is concern that there is tumour spread; the sur-
geon should mark with a suture or ink any areas of par-
ticular concern alternatively, the surgical margins can be
sampled by the pathologist when the surgeon is present.
If the tumour has destroyed or breached the cortex, the
margin can be sampled with a scalpel or knife.
11. The slab specimen should be photographed.
12. The soft tissues including major vascular struc-
tures around the dissected bone of the amputation or
resection specimen should be examined. Other appar-
ently uninvolved bones should be sliced sagitally and/or
coronally to look for foci of tumour or other lesions and
the major joints should be examined.
13. Representative tissue blocks taken for histology
from an amputation or resection specimen of a bone
tumour should include:-
￿ Blocks of tumour: a slab of all of the tumour in
b o n es h o u l db eb l o c k e do u ta n dap h o t o g r a p h i c
record kept of where the tissue blocks for histology
have been taken (Figure 1).
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tumour or bone not included in the slab if the
macroscopic appearance is unusual.
￿ Blocks of the previous incision site and biopsy
tract (if present).
￿ Blocks of the proximal bone resection margin at
the site of amputation or excision.
￿ Any abnormal-looking areas elsewhere in bone,
soft tissues, or skin.
￿ Lymph nodes: if grossly normal, only representa-
tive ones; if grossly abnormal or if there is clinical
suspicion of metastasis, all of them.
￿ Major vessels at the soft tissue amputation site.
14. The macroscopic description should note the fol-
lowing features:-
￿ Type and side (left/right) of amputation or bone
resection.
￿ The dimensions of the resection specimen (see
above).
￿ The gross presence or absence of exposed tumour
in bone or soft tissue of the specimen.
￿ The presence, position and dimensions of attached
skin and the presence of biopsy sites and surgical
scars.
￿ The anatomical site and location of the tumour
within bone (ie whether the lesion is in the epiphy-
sis, metaphysis or diaphysis of a long bone and
whether located in the medulla, the cortex or on the
surface of the bone).
￿ Dimensions of the tumour (in centimetres).
￿ Extent of bone, and soft tissue (including joint)
involvement.
￿ The presence or absence of necrosis (approximate
percentage) and other descriptive characteristics (eg
colour, calcification, hardness, gritty, haemorrhagic,
cystic) should be noted.
￿ The presence or absence or chemotherapy or
radiotherapy effect.
￿ Involvement or invasion of major structures (eg
nerve, major blood vessels).
￿ Presence of satellite lesions of tumour away from
the main tumour mass.
￿ Presence of lymph nodes and description of cut
surface of the nodes.
￿ Relation of the tumour to the resection margins;
the distance (in centimetres) should be measured.
In addition, a record should be kept of whether tissue
has been submitted for frozen section, cytogenetics,
molecular genetic analysis and other investigations.
8. Histological reporting of primary bone tumours
The following histological information should be
included in the surgical pathology report:-
￿ Tumour type (and subtype) according to WHO
histological classification.
￿ Tumour grade (if relevant)
￿ Morphological and cytological description of the
tumour; this may include details of the mitotic
count and degree of pleomorphism.
￿ Tumour necrosis (presence or absence and percen-
tage necrosis in the resection specimen).
￿ Extent of local tumour spread, in particular
whether the tumour involves specific anatomical
components or compartments (eg medullary cavity,
cortex, joint, extra-osseous soft tissues).
￿ Status of resection margins with regard to involve-
ment by tumour.
￿ Results of cytogenetic/molecular genetic investiga-
tions (if available).
￿ SNOMED coding of bone tumour (Table 3).
9. Ancillary investigations
9.1. Immunohistochemistry
Immunohistochemistry is useful in identifying or con-
firming the nature of cells in a bone tumour. Immuno-
histochemistry is particularly valuable in the differential
diagnosis of primary and secondary malignant tumours
of bone. Expression of epithelial markers, such as
epithelial membrane antigen and cytokeratin, may point
to a diagnosis of metastatic carcinoma; tumour cell
expression of specific antigens (eg PSA, TTF-1) may
indicate the likely primary origin. In the paediatric
population, expression of NB84a, synaptophysin and
chromogranin are useful in the identification of
Figure 1 Photograph of a slab taken through a specimen of an
osteosarcoma of the lower femur. This provides information on
the nature and site of sampled tissue blocks, the location of the
tumour, its relation to bone resection margins, and permits
calculation of the extent of tumour necrosis.
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Page 9 of 13metastatic neuroblastoma [31]. Expression of epithelial
markers is also seen in some primary bone tumours,
notably adamantinoma and chordoma [32,33]; the for-
mer also express podoplanin, and the latter S100 and
brachyury [34,35]. Other useful markers include Factor
8 related antigen, CD31, CD34 and podoplanin LYVE-1,
which are differentially expressed by endothelial cells in
specific vascular tumours [36].
In the diagnosis of malignant round cell tumours of
bone, expression of leukocyte common antigen (CD45)
indicates that tumour cells are of haematopoietic origin.
If a lymphoma is suspected, B and T cell markers, such
as CD19/CD20 and CD3 respectively, are useful. Mono-
clonal kappa or lambda light chain expression can be
identified in myeloma or plasmacytoma. Langerhans
cells in Langerhans cell histiocytosis can be identified
using antibodies directed against S100, and CD1a.
Expression of CD99 is useful in confirming the diagnosis
of Ewing’s sarcoma although it should be appreciated
that this antigen can be expressed in other round cell
tumours such as in lymphoblastic lymphoma, small cell
osteosarcoma and mesenchymal chondrosarcoma
[37,38]. Detection of FLI-1, a nuclear protein that is
involved in cell proliferation and tumourigenesis, is also
useful in the diagnosis of Ewing’s sarcoma [39]. FLI-1 is
normally expressed by endothelial cells and haemato-
poietic cells, including T lymphocytes and its expression
can be noted in lymphoblastic lymphoma and endothe-
lial cells of vascular neoplasms. WT1, a proliferation
marker, which represents a nuclear transcription factor,
is also useful in the diagnosis of small round cell
tumours, being found in Wilm’s tumour, lymphoblastic
lymphoma and occasionally neuroblastoma and lym-
phoma but not Ewing’s sarcoma [40]. Mutations in the
p53 gene result in the accumulation of p53 protein in
the nucleus. p53 expression may be elevated in some
malignant tumours of bone and overexpression may be
of prognostic significance [41,42].
9.2. Cytogenetic analysis
Cytogenetic analysis shows changes in the number and/
or structure of chromosomes in a tumour. Some of
these chromosomal abnormalities are tumour-specific
and are useful in bone tumour diagnosis [43]. Samples
of sterile, fresh tumour tissue are required for cytoge-
netic analysis. A thin slice of non-necrotic tumour tissue
should be submitted. The specimen is placed in tissue
culture medium (containing serum) and kept at room
temperature prior to transport to the laboratory; if there
is any delay, the specimen should be kept in a refrigera-
tor (not a freezer). Sample size should be 1 cm
3 or
more. Cells are grown in short term culture for karyo-
typing. Chromosome-specific probes can be labelled
with fluorescent dyes in order to identify chromosomes
or chromosome DNA sequences by fluorescence in situ
hybridisation (FISH). Cytogenetic analysis of bone
tumours is especially useful in the detection of the 11;22
translocation which is commonly found in Ewing’ss a r -
coma. Cytogenetic abnormalities have also been noted
in other tumours including osteochondroma, osteofi-
brous dysplasia, fibrous dysplasia, giant cell tumour,
osteosarcoma, chondrosarcoma and chordoma [3,4,43].
9.3 Molecular genetic analysis
Molecular genetic analysis is used to characterise
changes in gene and gene expression in tumour cells,
particularly translocations and mutations in oncogenes
and tumour suppressor genes [3,4]. A variety of meth-
ods can be used to identify these genetic abnormalities
including reverse transcriptase polymerase reaction (RT-
PCR) analysis in which a nucleotide sequence is ampli-
fied and then identified by appropriate DNA or RNA
probes. Snap frozen tissue is required for optimal mole-
cular genetic analysis using PCR techniques, but both
this procedure (and fluorescent in situ hybridisation)
can be used on paraffin-embedded material. Molecular
genetic analysis is particularly useful in the diagnosis of
Ewing’s sarcoma, which is associated with a characteris-
tic reciprocal translocations that involve the EWS gene
on chromosome band 22 q12 and genes from different
members of the ETS family of transcription factors
[44-46]. The most common of these translocations is t
[11; 22] (q24; q12), which is present in nearly 85% of
cases of Ewing’s sarcoma; this results in a tumourigenic
fusion protein composed of the 5’-e n do ft h eE W S
gene and 3’- end of the ETS family gene FLI1: This
EWS-FLI1 fusion product has been reported in other
malignant round cell tumours including neuroblastoma
and mesenchymal chondrosarcoma [47,48]. The second
most common translocation is t(21; 22) (q24, q12),
which involves the same segment of the EWS gene com-
bined with the 3’end of the ETS family gene ERG. The
EWS gene may combine with other ETS family genes in
other translocations including t(7; 22), t(17; 22), and t(2;
22). Molecular studies are also useful in identifying loss
or mutation in certain tumour suppressor genes, such as
p53 and the retinoblastoma gene, both of which are
associated with the pathogenesis of osteosarcoma
[49-53]. The loss of both functional alleles by either
deletion or mutation results in unrestrained cell growth.
9.4. Other ancillary investigations
Flow cytometry is not routinely employed for tumour
diagnosis as it does not accurately distinguish between
benign and malignant bone tumours of bone. I can,
however, provide supportive evidence that may favour
the diagnosis of a benign or malignant tumour and in
some cases provides information on prognosis and
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measurement of a number of features including cell
size, viability, cell cycle time and DNA ploidy as well as
other cytological parameters. With regard to DNA
ploidy, tumours are generally divided into diploid and
aneuploid. DNA aneuploidy indicates an abnormal
amount of DNA in a tumour cell population relative to
normal (diploid) cells. DNA aneuploidy has been docu-
mented in benign bone tumours and does not equate
with malignancy. However, aneuploidy is more prevalent
in high grade malignant tumours and is an independent
risk factor for predicting metastasis. Electron micro-
scopy is also not employed routinely for tumour diagno-
sis; it can in some cases help in establishing the
diagnosis of some bone tumours [56,57]; for example
identifying Birbeck granules in Langerhan’s cell histiocy-
tosis or cytoplasmic glycogen in Ewing’s sarcoma.
10. Assessment of preoperative chemotherapy
Preoperative chemotherapy is commonly used with limb
salvage procedures for the treatment of high-grade sar-
comas, particularly osteosarcoma and Ewing’s sarcoma.
To determine the effect of chemotherapy it is generally
required to quantify the extent of tumour necrosis as a
percentage of the total tumour area [58]. For osteosar-
comas, chemotherapy-induced necrosis of 90% or more
has a greater than 90% disease-free survival, compared
with less than 50% in patients with less than 90%
tumour necrosis [58-61]. For Ewing’s sarcoma, signifi-
cant necrosis, according to most series, appears to be
roughly defined as greater than 90% of the microscopic
tumour mass [62-67]. Tumours demonstrating such
massive necrosis are associated with a favourable prog-
nosis, whereas those with less necrosis are associated
with poor survival.
To determine the extent of necrosis in an osteosar-
coma or Ewing’s sarcoma specimen, the slab specimen
of the resected bone containing the tumour provides
the template for histological analysis [5-7,66]. A photo-
graph or radiograph of the slice is taken and the site
of each numbered block marked on a grid pattern dia-
gram. Additional blocks are also taken in a plane at
right angles to this set of blocks to determine the full
extent of the tumour. As indicated earlier, blocks
should also be taken from other representative areas of
the specimen including areas of unusual appearance in
bone and soft tissue surrounding the tumour and pos-
sible satellite lesions in order to get a clear picture of
the volume and extent of the tumour. Treated osteo-
sarcomas may contain large atypical cells with hyper-
chromatic nuclei, smudged or clumped chromatin and
vacuolated cytoplasm in areas of necrosis, calcification
or fibrosis [66,67]. The nature of these cells is not cer-
tain but they are currently considered to represent
viable tumour cells in assessing the extent of tumour
necrosis. Other effects of chemotherapy on tumour
histology include ghost-like cells with loss of nuclear
and cytoplasmic detail, granulation tissue formation,
fibrosis, haemosiderin deposition, mucinous change
and inflammation.
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